Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.2% - Should You Sell?

Key Points

• Eli Lilly's share price decreased by 1.2% to $753.52, while trading volume surged to 7.3 million shares, significantly above its average volume of 4.1 million.
• Analysts have mixed sentiments on the stock, with reports indicating a range of ratings: one "strong buy," fourteen "buy," and nine "hold," with a consensus price target of $939.61.
• Eli Lilly's recent quarterly earnings report showed an EPS of $6.31, surpassing estimates and reflecting a 37.6% increase in revenue compared to the same quarter last year.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price fell 1.2% during mid-day trading on Friday . The company traded as low as $749.20 and last traded at $753.52. 7,309,685 shares changed hands during mid-day trading, an increase of 78% from the average session volume of 4,104,780 shares. The stock had previously closed at $762.93.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LLY. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Berenberg Bank reaffirmed a "hold" rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Price Performance

The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a 50-day moving average of $739.17 and a 200-day moving average of $772.98. The firm has a market capitalization of $713.18 billion, a price-to-earnings ratio of 49.25, a price-to-earnings-growth ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is 39.22%.

Insider Activity

In other news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in shares of Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after buying an additional 2,568 shares during the last quarter. Breed s Hill Capital LLC boosted its holdings in shares of Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock valued at $1,101,000 after buying an additional 969 shares during the last quarter. Finally, Continuum Advisory LLC boosted its holdings in shares of Eli Lilly and Company by 6.2% in the 4th quarter. Continuum Advisory LLC now owns 1,594 shares of the company's stock valued at $1,230,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.